Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7565020 in healthy volunteers and chronic hepatitis B patients
NCT05763576Phase 1Terminated
- Sponsor
- Roche
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of RO7565020 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Roche. Primary endpoints: Adverse Events at 32 weeks, Serious Adverse Events at 32 weeks and 1 more. Started Apr 2023; status: terminated.
02
Drugs
RO7565020
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05763576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763576.